About: Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in South Korea. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme (GBM), lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: A$0.04 (+10.53%)
IVX ASX Invion Ltd
Invion Ltd share price
IVX price activity
Último preço
$ 0,040
Variação (24h)
0,00 AUD (10,53%)
Volume
176.44K
Volume (média 4 sem.)
-
Abertura
$ 0,04
Variação do dia
$ 0,04 - $ 0,04
Fechamento anterior
$ 0,04
Último negócio
05 Oct, 4:19 am GMT+0
Atrasado
05 Oct, 4:19 am GMT+0
IVX price performance
Atrasado
05 Oct, 4:19 am GMT+0
quote.marketSignals